Early Detection Research Network

Boeri miRNA signature of diagnosis of lung cancer

This biomarker is also known as:
  • Boeri miRNA signature of diagnosis of lung cancer,


miRNA expression analyses in plasma samples collected 1-2 years before the onset of disease, at the time of CT detection and in disease-free smokers enrolled in the screening trial, resulted in the generation of miRNA signatures with strong predictive, diagnostic, and prognostic potential (area under the ROC curve > or = 0.85). The signature of diagnosis of lung cancer is comprised of 16 ratios composed from 13 miRNAs: 21, 92a, 140-3p, 17, 106a, 140-5p, 660, 19b, 451, 30c, 15b, 28-3p, 486-5p. (from PMID:21300873)


There are no datasets associated with this biomarker.

QA State: Curated
HGNC Name:

Panel Details

No member markers defined for this panel.

The following organs have data associated with this biomarker…


Phase: One
QA State: Curated


Overall, these findings strengthen the observation that circulating miRNA in plasma is detectable well before clinical disease detection by spiral CT, indicating the possibility to select high-risk groups on the basis of miRNA profiling.

Performance Comment

Plasma samples collected at surgery or at time of disease detection by spiral CT were compared with pools of disease-free individuals to identify a miRNA profile associated with lung cancer diagnosis. The signature for diagnosis of lung cancer, a panel of 16 ratios involving 13 different miRNAs, classified 16 of 19 patients with a sensitivity of 84% and a specificity of 80% in the training set. In the validation set plasma samples, 12 of 16 patients were correctly discriminated, with a sensitivity of 75% and a specificity of 100% (AUC-ROC = 0.88, P < 0.0001). This diagnostic signature was then used for class prediction of predisease plasma samples in the same series. In the training set, 11 of 20 (55%) cases were classified as individuals with disease and, very interestingly, 10 of these 11 cases were characterized by poor prognosis (dead or alive with disease) or belonged to the group of patients identified from 3rd to 5th y of screening. In the validation set, similar results were obtained, with presence of the disease signature already in 10 of 15 (66.6%) predisease plasma samples.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.